INVESTOR RELATIONS

News

Date Title and Summary Additional Formats
Toggle Summary NantKwest Announces Phase 1 Results for First-in-Human PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) in Patients with Locally Advanced or Metastatic Solid Cancers
First-in-human trial shows no dose-limiting toxicities in six subjects treated as out-patients with PD-L1.t-haNK off-the-shelf CAR NK cell therapy with potential to overcome limitations of CAR-T therapies for solid tumors CULVER CITY, Calif. --(BUSINESS WIRE)--Dec. 2, 2019-- NantKwest, Inc.
View HTML
Toggle Summary NantKwest Announces Presentation at the American Society of Hematology (ASH) Annual Meeting; NK-92 Phase 1 Clinical Data on Dosing and Long-Term Survival in Relapsed Hematological Malignancies
CULVER CITY, Calif. --(BUSINESS WIRE)--Dec. 3, 2015-- NantKwest, Inc. (Nasdaq: NK), a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using natural killer cells to treat cancer, infectious diseases and inflammatory diseases, today announced that
View HTML
Toggle Summary NantKwest Announces Presentation of Positive Phase 2 Clinical Data of Natural Killer Cell Therapy in Metastatic Merkel Cell Carcinoma at SITC 2019
Durable Responses Demonstrated in 2 of 7 Patients with Refractory Metastatic MCC Data Supportive of Planned Off-the-Shelf Clinical Trial to Confirm Activity and Safety CULVER CITY, Calif. --(BUSINESS WIRE)--Nov. 7, 2019-- NantKwest Inc. (Nasdaq: NK), a next generation, clinical-stage immunotherapy
View HTML
Toggle Summary NantKwest Announces Presentation of Preclinical Data of HER2.taNK at the San Antonio Breast Cancer Symposium (SABCS)
“Novel protocol combining metronomic Nant-paclitaxel with HER2-targeted natural killer cells (innate immunotherapy) for HER2-positive metastatic breast cancer” CULVER CITY, Calif. --(BUSINESS WIRE)--Dec. 9, 2015-- NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage
View HTML
Toggle Summary NantKwest Announces Presentations at the Upcoming 16th Annual Meeting of the Society for Natural Immunity
CULVER CITY, Calif. --(BUSINESS WIRE)--Oct. 3, 2016-- NantKwest, Inc (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of the immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory
View HTML
Toggle Summary NantKwest Announces Presentations at Upcoming Investment Conference Meetings
CULVER CITY, Calif. --(BUSINESS WIRE)--Nov. 2, 2015-- NantKwest Inc. (Nasdaq:NK) today announced that the company will be presenting at the following upcoming investment conferences in November and December: Citi 2015 Global Healthcare Conference, Jefferies 2015 Global Healthcare Conference and the
View HTML
Toggle Summary NantKwest Announces Presentations at Upcoming Investment Conferences
CULVER CITY, Calif. --(BUSINESS WIRE)--Sep. 10, 2016-- NantKwest, Inc (NASDAQ:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory
View HTML
Toggle Summary NantKwest Announces Pricing of Initial Public Offering
CULVER CITY, Calif.--( BUSINESS WIRE )--NantKwest, Inc. (formerly Conkwest, Inc.), a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer, infectious diseases and inflammatory diseases, announced today the
View HTML
Toggle Summary NantKwest Announces Promising First in Human Clinical Results of 300 Doses Of CD16 Targeted, Off-The-Shelf Cryopreserved Natural Killer Cells (haNK) in a Novel Cancer Memory Vaccine Immunotherapy
Combination in 30 Patients with Advanced Metastatic Cancer Refractory to Multiple Previous Therapies Zero Incidence of Cytokine Release Syndrome in Any of the 300 Doses in 30 Patients All Patients Received NK Cell Infusion and Novel Cancer Memory Vaccine Combination as Outpatients with No
View HTML
Toggle Summary NantKwest Announces Prostate Cancer Foundation $1 Million Challenge Award to Study a Novel Natural Killer Cell Therapy in Prostate Cancer
LOS ANGELES --(BUSINESS WIRE)--Aug. 26, 2015-- NantKwest (Nasdaq:NK), working with Ganesh Palapattu, MD and his team at the University of Michigan , along with Karen Knudsen , PhD and her group at Thomas Jefferson University , announced a $1 Million Challenge award from the Prostate Cancer
View HTML